BRPI0515030A - derivados de purina como agonistas de receptor de adenosina a3 e a1 - Google Patents

derivados de purina como agonistas de receptor de adenosina a3 e a1

Info

Publication number
BRPI0515030A
BRPI0515030A BRPI0515030-2A BRPI0515030A BRPI0515030A BR PI0515030 A BRPI0515030 A BR PI0515030A BR PI0515030 A BRPI0515030 A BR PI0515030A BR PI0515030 A BRPI0515030 A BR PI0515030A
Authority
BR
Brazil
Prior art keywords
receptor agonists
nucleosides
adenosine receptor
purine derivatives
agonists
Prior art date
Application number
BRPI0515030-2A
Other languages
English (en)
Inventor
Kenneth A Jacobson
Bhalchandra V Joshi
Susanna Tchilibon
Original Assignee
Us Gov Health & Human Serv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Health & Human Serv filed Critical Us Gov Health & Human Serv
Publication of BRPI0515030A publication Critical patent/BRPI0515030A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Pregnancy & Childbirth (AREA)

Abstract

DERIVADOS DE PURINA COMO AGONISTAS DE RECEPTOR DE ADENOSINA A~ 3~ E A~ 1~. São revelados (N) -metanocarba adenina nucleosídeos a fórmula: como agonistas de receptor de adenosina A~ 3~ altamente potentes, composições farmacêuticas compreendendo tais nucleosídeos e um método de uso desses nucleosídeos, onde R~ 1~R~ 6~ são conforme definidos no relatório descritivo. Esses nucleosídeos são contemplados para uso no tratamento de várias doenças, por exemplo, inflamação, isquemia cardíaca, acidente vascular, asma, diabetes e arritmias cardíacas. A invenção também provê compostos que são agonistas de ambos receptores de adenosina A~ 1~ e A~ 3~ para uso na cardioproteção.
BRPI0515030-2A 2004-09-09 2005-09-02 derivados de purina como agonistas de receptor de adenosina a3 e a1 BRPI0515030A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60882304P 2004-09-09 2004-09-09
PCT/US2005/031678 WO2006031505A1 (en) 2004-09-09 2005-09-02 Purine derivatives as a3 and a1 adenosine receptor agonists

Publications (1)

Publication Number Publication Date
BRPI0515030A true BRPI0515030A (pt) 2008-07-01

Family

ID=35517431

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0515030-2A BRPI0515030A (pt) 2004-09-09 2005-09-02 derivados de purina como agonistas de receptor de adenosina a3 e a1

Country Status (10)

Country Link
US (1) US7825126B2 (pt)
EP (1) EP1794162A1 (pt)
JP (2) JP2008512457A (pt)
KR (1) KR20070050484A (pt)
CN (1) CN101056879B (pt)
AU (1) AU2005285284B2 (pt)
BR (1) BRPI0515030A (pt)
CA (1) CA2601996A1 (pt)
IL (1) IL181716A0 (pt)
WO (1) WO2006031505A1 (pt)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GT200500281A (es) * 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
GB0500785D0 (en) * 2005-01-14 2005-02-23 Novartis Ag Organic compounds
ATE549337T1 (de) 2006-04-21 2012-03-15 Novartis Ag Purinderivate zur verwendung als adenosin-a2a- rezeptoragonisten
GB0607950D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
GB0607944D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
GB0607953D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
PL2049127T3 (pl) 2006-05-23 2015-03-31 Univ Connecticut N-metanokarbapochodne do leczenia chorób serca
ES2361886T3 (es) * 2006-06-27 2011-06-24 Cbt Development Limited Profármacos adenosina acetil 2',3'-metilideno novedosos para uso como profármacos para agonistas del receptor adenosina.
EP1889846A1 (en) 2006-07-13 2008-02-20 Novartis AG Purine derivatives as A2a agonists
WO2008023362A2 (en) * 2006-08-21 2008-02-28 Can-Fite Biopharma Ltd. Use of a combination of methotrexate and an a3ar agonist for the treatment of cancer
EP1903044A1 (en) * 2006-09-14 2008-03-26 Novartis AG Adenosine Derivatives as A2A Receptor Agonists
JP2010508835A (ja) * 2006-11-10 2010-03-25 ノバルティス アーゲー シクロペンテンジオールモノアセテート誘導体
AU2008270735C1 (en) 2007-06-29 2014-03-06 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Dendrimer conjugates of agonists and antagonists of the GPCR superfamily
CN103664637B (zh) 2007-06-29 2016-02-03 奥克塞拉有限公司 用于治疗眼科疾病和紊乱的炔基苯基衍生化合物
PL2227234T3 (pl) 2007-10-15 2014-11-28 Can Fite Biopharma Ltd Sposób wywoływania proliferacji hepatocytów i jego zastosowania
CA2720037C (en) 2008-03-31 2016-08-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Purine derivatives as a3 adenosine receptor-selective agonists
US8916570B2 (en) 2008-03-31 2014-12-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A3 adenosine receptor agonists and antagonists
US9181253B2 (en) 2008-08-01 2015-11-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adenosine receptor agonists, partial agonists, and antagonists
CA2732320C (en) 2008-08-01 2017-08-29 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A3 adenosine receptor antagonists and partial agonists
EP2507241A1 (en) 2009-12-02 2012-10-10 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Methanocarba adenosine derivatives and dendrimer conjugates thereof
ES2654363T3 (es) 2010-02-22 2018-02-13 University Of Connecticut Derivados de AMP para tratar enfermedades cardíacas
US20130109645A1 (en) 2010-03-31 2013-05-02 The united States of America,as represented by Secretary,Dept.,of Health and Human Services Adenosine receptor agonists for the treatment and prevention of vascular or joint capsule calcification disorders
EP2669292B1 (en) 2011-01-26 2017-03-29 Beijing KBD Pharmaceuticals Co., Ltd. Ribofuranosyl purine compounds for treating diseases associated with platelet aggregation
PE20160685A1 (es) 2013-10-04 2016-07-23 Infinity Pharmaceuticals Inc Compuestos heterociclicos y usos de los mismos
WO2015080940A1 (en) * 2013-11-27 2015-06-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A3 adenosine receptor agonists
SG10201808053XA (en) 2014-03-19 2018-10-30 Infinity Pharmaceuticals Inc Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
US9708348B2 (en) 2014-10-03 2017-07-18 Infinity Pharmaceuticals, Inc. Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof
US10160761B2 (en) 2015-09-14 2018-12-25 Infinity Pharmaceuticals, Inc. Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same
WO2017185061A1 (en) 2016-04-21 2017-10-26 Astrocyte Pharmaceuticals, Inc. Compounds and methods for treating neurological and cardiovascular conditions
US10919914B2 (en) 2016-06-08 2021-02-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
KR101820909B1 (ko) * 2017-07-07 2018-01-23 퓨쳐메디신 주식회사 아데노신 유도체를 포함하는 만성신장질환 예방 및 치료용 약학적 조성물
JP7311855B2 (ja) 2018-02-09 2023-07-20 アストロサイト ファーマシューティカルズ， インコーポレイテッド 嗜癖および関連する障害を処置するための化合物および方法
WO2020069068A1 (en) 2018-09-26 2020-04-02 Astrocyte Pharmaceuticals, Inc. Polymorphic compounds and uses thereof
IL307967A (en) * 2021-04-28 2023-12-01 Astrocyte Pharmaceuticals Inc Purine nucleosides, their intermediates and methods for their preparation
WO2022241249A1 (en) * 2021-05-13 2022-11-17 Promega Corporation Bioluminescent detection of dna synthesis
WO2025019529A1 (en) * 2023-07-17 2025-01-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services 5-ht 2b serotonin receptor antagonists, pharmaceutical compositions thereof, and methods of use thereof
CN117503766B (zh) * 2024-01-04 2024-04-26 中国康复研究中心 Pld抑制剂在制备治疗脊髓损伤的药物中的用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5688774A (en) * 1993-07-13 1997-11-18 The United States Of America As Represented By The Department Of Health And Human Services A3 adenosine receptor agonists
EP0708781B1 (en) * 1993-07-13 2001-10-04 THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, Department of Health and Human Services A 3 adenosine receptor agonists
GB9723589D0 (en) * 1997-11-08 1998-01-07 Glaxo Group Ltd Chemical compounds
US6586413B2 (en) * 1999-11-05 2003-07-01 The United States Of America As Represented By The Department Of Health And Human Services Methods and compositions for reducing ischemic injury of the heart by administering adenosine receptor agonists and antagonists
EP1252160B1 (en) * 2000-01-14 2006-08-16 The Government of the United States of America, as represented by the Secretary of the Department of Health and Human Services Methanocarba cycloalkyl nucleoside analogues
EP1241176A1 (en) * 2001-03-16 2002-09-18 Pfizer Products Inc. Purine derivatives for the treatment of ischemia
US20050261237A1 (en) * 2003-04-25 2005-11-24 Boojamra Constantine G Nucleoside phosphonate analogs
WO2006113204A2 (en) * 2005-04-15 2006-10-26 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Thymidine derivatives for treatmemt of kaposi's sarcoma
US7867983B2 (en) * 2007-03-29 2011-01-11 The University Of Connecticut Methods to protect skeletal muscle against injury

Also Published As

Publication number Publication date
EP1794162A1 (en) 2007-06-13
AU2005285284B2 (en) 2011-06-02
US7825126B2 (en) 2010-11-02
JP2008512457A (ja) 2008-04-24
CA2601996A1 (en) 2006-03-23
CN101056879B (zh) 2011-10-05
JP2012229215A (ja) 2012-11-22
US20070232626A1 (en) 2007-10-04
WO2006031505A1 (en) 2006-03-23
KR20070050484A (ko) 2007-05-15
AU2005285284A1 (en) 2006-03-23
CN101056879A (zh) 2007-10-17
IL181716A0 (en) 2007-07-04

Similar Documents

Publication Publication Date Title
ECSP088511A (es) Agonistas del receptor del neuropeptido-2
ECSP003713A (es) Derivados de purina
CR9748A (es) Derivados de xantina como agonistas selectivos de hm74a
ECSP003712A (es) Derivados de la purina
NO20085099L (no) Puritonderivativer som HM74A agonister
CR10874A (es) Polimorfos de sal de succinato 2-[6-(3-amino-piperidin-1-ilo)-3 metil-2,4-dioxo-3,4-dihidro-2h-pirimidin-1-ilmetil]-4-fluoro benzonitrilo y metodos para el uso de los mismos
GT200900007A (es) Derivados de purina como agonistas de a2a
BRPI0510762A (pt) derivados de tetraidronaftiridina úteis como ligantes do receptor de histamina h3
BR0302965A (pt) Composto e método de tratar doenças mediadas por receptores de adenosina a2b
ECSP066391A (es) [1,8] naftiridin-2-onas y compuestos relacionados para el tratamiento de la esquizofrenia
EA200800162A1 (ru) Новые фармацевтические композиции с замедленным высвобождением и способы их получения
NO20072548L (no) Xantinderivater med HM74A reseptoraktivitet
BRPI0912923A8 (pt) Composto que consiste de um oligonucleotídeo modificadpo composto de 12-30 nucleosídeos ligados, compostos que compreende um oligonucleotídeo modificado que compreende pelo menos 12 nucleosídeos ligados, composto que compreende um oligonucleotídeo modificado que compreende nucleosídeos ligados, e, uso de um composto
NO20085257L (no) Purinonderivater som HM74a-agonister
BRPI0609704B8 (pt) compostos derivados de fosforamidato, seus usos, composições farmacêuticas que os compreendem, métodos de preparação das referidas composições e processo para preparação de um composto
BRPI0508724A (pt) derivados do fenilaminoetanol como agonistas do receptor beta2
BRPI0918517B8 (pt) composto, composição farmacêutica, e, uso de um composto
MX376743B (es) Síntesis de lactonas de ácido resorcílico útiles como agentes terapéuticos
NO20061952L (no) Pyrimidin-2-aminderivater og deres anvendelse som A2B-adenosinreseptorantagonister
TW200740814A (en) Compounds
BRPI0414643A (pt) composto, composições farmacêuticas, e, uso de um composto
NO20061981L (no) Arylindenopyridiner og arylindenopyridiner og deres anvendelse som adenosin A2A reseptoragonist
BRPI0511424A (pt) composto, composição farmacêutica, uso de um composto, método de tratamento ou profilaxia de doenças inflamatórias, e, processo para a preparação de um composto
DOP2003000587A (es) AGONISTAS DEL RECEPTOR ß3-ADRENERGICO
BRPI0611202C1 (pt) compostos de benzimidazola-carboxamida como agonistas do receptor 5-ht4

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2269 DE 01/07/2014.